Publications
Specialty
Search
Oncology
10/24/2024
According to the phase 3 AMBASSADOR trial, adjuvant pembrolizumab significantly improved disease-free survival among patients with high-risk muscle-invasive urothelial carcinoma.
Oncology
10/24/2024
According to the phase 3 NIAGARA trial, the addition of perioperative durvalumab to neoadjuvant chemotherapy significantly improved event-free survival and overall survival among cisplatin-eligible patients with operable, muscle-invasive bladder cancer.
Neurology
10/24/2024
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke.
Psych Congress Network
10/24/2024
Test your knowledge with this quick quiz!
EP Lab Digest
10/24/2024
In this interview, EP Lab Digest speaks with Sorin Ștefan Popescu, MD, and Roland Richard Tilz, MD, about their research comparing the safety and efficacy of a venous vascular closure system to the standard of care (figure-of-8 suture and manual compression) following atrial fibrillation (AF) ablation.
Lymphoma, Leukemia & Myeloma Network, Oncology
10/24/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, discusses treatment possibilities for patients with
R/R multiple myeloma when immune therapies, such as antibody drug conjugates, CAR T-cell therapy, and bispecific antibodies, fail.
First Report Managed Care
10/24/2024
Pfizer receives FDA approval for Abrysvo, the first RSV vaccine for adults under 50 at risk of lower respiratory tract disease, marking a significant milestone in respiratory health.
EP Lab Digest
10/24/2024
The reprocessing company seeks to further improve its already impressive impact on greenhouse gas emissions in healthcare
Gastroenterology
10/24/2024
Adenoma detection was significantly lower in cases of bowel preparation rated ‘fair’ or lower.
ePlasty, Surgery
10/23/2024
Regenerative peripheral nerve interfaces (RPNI) effectively treat non-extremity neuropathic pain. A review of seven patient cases highlights diverse trauma-related nerve injuries.
Journal of Clinical Pathways
10/23/2024
In this interview, Jessica Paulus, ScD, senior director of real-world research at Ontada, discusses trends in advanced non–small cell and small cell lung cancer diagnoses, the impact of the COVID-19 pandemic on screening, and the need for more public health initiatives.
ePlasty, Surgery
10/23/2024
A retrospective study of 69 patients compared air versus saline intraoperative fill in 2-stage breast reconstruction, focusing on postoperative outcomes.
Oncology
10/23/2024
According to results from the phase 3 ADRIATIC trial, adjuvant durvalumab significantly extended survival compared to placebo among patients with limited-stage small cell lung cancer.
Wound Care
10/23/2024
DEBx Medical has initiated a 40-patient pilot RCT to examine the safety/efficacy of chemical debridement and curettage in treatment of venous and mixed etiology leg ulcers with primary outcome of percentage wound reduction at 12 weeks. Not yet recruiting; estimated completion is April 2025. clinicaltrials.gov
Wound Care
10/23/2024
Tactile Medical announces the launch of the next-generation NIMBL pneumatic compression lymphedema platform in the U.S. for the treatment of upper extremity lymphedema. Nimbl is 68% lighter and 40% smaller than previous-generation devices.
Wound Care
10/23/2024
BoStem Technologies announces breakthrough results of BioREtain-processed membranes RE-AC (AmnioWrap2) demonstrating a clear advantage in 12-week DFU healing rates compared to SoC. Results of the study have been published in the recent issue of the International Wound Journal.
Wound Care
10/23/2024
Celularity expands its current biomaterial portfolio with the acquisition of Rebound, a full-thickness placental-derived allograft matrix, from Sequence LifeScience. The company expects Rebound sales to contribute revenue in Q424 and fulfill expected FY24 biomaterial sales.
Pharmacy Learning Network
10/23/2024
Breckenridge Pharmaceutical Inc. is recalling 7107 bottles of duloxetine delayed-release capsules because of an N-nitroso duloxetine impurity.
Pharmacy Learning Network
10/23/2024
Accord Healthcare Inc. is recalling vials of cisplatin injection after samples failed to meet impurity/degradation specifications during testing.